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1. Abstract
Background: Tranexamic acid (TXA) is an antifibrinolytic used for controlling
hemorrhaging in patients. It’s regular application in trauma centers could be vital in
reducing all-cause mortality for hemorrhaging secondary to traumatic injury but there
are still concerns about possible side effects and populations at greater risk of
complications. The possible use of predictive measures such as thrombelastography
(TEG) and conventional coagulation testing (CCT) in detecting early markers of TXA
risks are still unconfirmed, and unfortunately there is a time restriction of 3 hours for
TXA to be effective in reducing all-cause mortality.
Objective: Our objective is to observe outcomes of patients who received TXA to see if
there were any significant associated thromboembolic complications, and to evaluate
TEG and CCT results to find any values that can be used as predictive measures for
anticipating these complications in the future. Our ultimate goal is to support the case
for TXA to be implemented more frequently in pre-hospital settings to meet the 3-hour
administration range.
Methods: This was a retrospective study of trauma patients at the Oregon Health and
Science University (OHSU) trauma center. Data was obtained from patients at risk of
hemorrhagic shock with an Injury Severity Score (ISS) >9. Patients who received TXA
between 2017 and 2019 were crossmatched with patients who did not receive TXA by
ISS score. Parametric and non-parametric tests were used to find significance (p-value<
0.05) based on distribution of the data.
Results: Mortality rate in the TXA group was 2.7% lower than the non-TXA group but
had a slightly longer hospital length of stay. The TXA group also had a higher rate of
penetrating mechanism of injuries which may have been reflected in the higher injury
scores in the abdomen and lower extremity, but we did not see an increase in blood
products used. There was also a trend toward significance of DVT occurrence in the
TXA group. Upon comparison of TEG values, significance (<0.05) was only found in the
alpha angle.
Conclusion: Longer hospital length of stay may be due to the high rate of penetrating
injuries which would typically require more time to recover due to complications if
lacerations were to occur on multiple organs. The higher rate of DVT in TXA may be
due to OHSU’s preventative screening of DVTs as opposed to other hospitals which
only screen for DVTs if a patient is symptomatic. We were also limited by a small
sample size, and only having data from a single hospital. TEG and CCT results
contained no predictive indicators of thromboembolic complications, which is most likely
due to the machine not being sensitive enough. Overall there is no indication of risk
associated with administration of TXA. A larger study would be needed to have more
power behind our results to confirm our findings.

1. Introduction
Exploration as to whether the antifibrinolytic agent, tranexamic acid (TXA),
should be added to the armamentarium of trauma centers has been sparked by results
that came out of the CRASH-2 trial. This randomized-controlled trial showed significant
reduction of all-cause mortality and number of blood products needed for patients at risk
for exsanguination when administered 1 bolus of tranexamic acid over 10 minutes
followed by an infusion of 1 g over 8 hours1. Hyperfibrinolysis and acquired fibrinogen
deficiency after injury has been correlated with an increased hemorrhage and mortality
risk 2 so tranexamic acid is used to slow the rate of fibrinolysis, or the breakdown of
blood clots, to prevent patients from further bleeding out and to allow doctors more time
to control bleeding. While the process of fibrinolysis is fundamental for the pathogenesis
of trauma-induced coagulopathy (TIC), antifibrinolytic agents such as TXA have been
shown to be safe and successful for treatment of acute hemorrhage and TBI recovery3 .
Thromboembolic complications and long-term organ failure may occur with patients
presenting the phenotype for near inhibition of fibrinolysis after injury if administered
TXA 4 , so further research is needed to better understand who is at risk for severe
complications from TXA. While some laboratory tests, such as thrombelastography
(TEG) and conventional coagulation testing (CCT), can possibly be used to
preemptively determine if a patient poses minimal risk for complications, the
unpredictability of trauma and the 3-hour time limit5 following injury for administering
TXA restricts the amount of testing that can be done before-hand.

1

Roberts I and Shakur H, “The CRASH-2 Trial: A Randomised Controlled Trial and Economic Evaluation of the
Effects of Tranexamic Acid on Death, Vascular Occlusive Events and Transfusion Requirement in Bleeding Trauma
Patients,” Health Technology Assessment (Winchester, England) 17, no. 10 (March 2013): 1–79,
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Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled
Trial,” Lancet (London, England) 394, no. 10210 (November 9, 2019): 1713–23,
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CRASH-3 trial collaborators (2019), “Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and
Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled
Trial,” 3.

A. Traumatic Hemorrhage
The leading cause of death for Americans age one to 46 years is hemorrhage
secondary to traumatic injury6. There are four classification of hemorrhage; 1) Blood
loss of up to 15%, regular to minimally elevated HR, BP, and RR; 2) 15-30% blood loss,
cool and calmly hands, tachycardia, tachypnea, and a decreased diastolic pulse
pressure; 3) 30-40% of blood volume loss, changes in Glasgow Coma Score (GCS),
hypotension, elevated HR and RR, and diminished urine output; 4) >40% of blood
volume loss, hypotensive, narrowed pulse pressure, tachycardia is marked cold and
pale skin, absent urine output, and delayed capillary refill7. Hemorrhaging can be
controlled with the use of tourniquets, hemostatic dressings, antifibrinolytic agents, and
other various agents to control the source of bleeding8. Bleeding needs to be stopped or
controlled enough to then replace the fluid lost as soon as possible.
B. Tranexamic Acid
TXA’s primary mechanism of action is to reduce clot lysis by inhibiting fibrinolysis. It
does this by blocking the fibrin binding site of plasminogen where it would bind to the
II-PA factor and become plasmin. The two proteins are then unable to induce the
degradation of fibrin which is the primary protein that forms blood clots during
fibrinolysis9. While TXA has been shown to reduce all-cause mortality and the amount of
blood products needed with traumatic injury10, it is also easily transported, is more
readily available in the field where blood is not, and affordable. Researchers found that
by administering TXA within the 3-hour window post-injury, the cost per life-year (LY)
gained from cause-specific mortality was only $64. While TXA has a time-dependent
beneficial effect, the immediate administration improves survival by 70%, but after that
there is approximately a 10% loss of effectiveness every 15 minutes TXA is not
administered within the 3-hour window11.
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Chambers, J. A., Seastedt, K., and et al., “A U.S. Military Installation’s Model for Implementation of a Rapid
Hemorrhage Control Program,” Military Medicine 184, no. 3–4 (March 1, 2019): 67–71,
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C. Thrombelastography (TEG)
Thrombelastography (TEG) is a test used to quantitatively measure the clotting
ability of whole blood. It is a non-invasive method with the following variables: Time to
clot formation (R), kinetics (K), rate of fibrin cross-linking (alpha angle), maximum
amplitude/clot strength (MA), and lysis at 30 minutes after MA (LY30) (Figure 1). Some
variables would possibly assist more than others in determining clotting characteristics
important to understanding the effect of TXA in blood, or a patient’s natural clotting
tendency. Thrombelastography is the best test to determine hypo- and
hyper-coagulation states in polytrauma patients compared to CCT12. If a patient is
determined to be hypercoagulable, then they would be at the most risk for developing
thromboembolic complications if administered TXA. Hypocoagulation and
hypercoagulation can be defined in TEG results if two of the following characteristics
are met for each. For hypo-coagulation, the range is; R > 27, MA < 44 or G < 3.6,
while for hypercoagulation, it is; R < 9, MA > 64 or G > 8.513. Clot lysis, or LY30, is
also an important variable since this is what describes the rate that a blood clot breaks
down. For a patient who received TXA the percent the clot breaks down should be lower
than a patient who did not receive TXA. LY30 greater than 3% would be a marker for
hyperfibrinolysis which is an indicator that the patient needs to be treated with
antifibrinolytics14.
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Martínez, Juame Tur et al., “Comparison Between Thromboelastography and Conventional Coagulation Test:
Should We Abandon Conventional Coagulation Tests in Polytrauma Patients?,” Elsevier 96, no. 7 (September 2018):
443–49, https://doi.org/10.1016/j.cireng.2018.07.012.
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Focusing on Pre-Hospital Trauma Care,” European Journal of Trauma and Emergency Surgery, September 14, 2020,
https://doi.org/10.1007/s00068-020-01493-z.
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Chapman, Michael MD, “Fibrinolysis Greater than 3% Is the Critical Value for Initiation of Antifibrinolytic
Therapy,” The Journal of Trauma and Acute Care Surgery 75, no. 6 (December 2013): 961–67,
https://doi.org/10.1097/TA.0b013e3182aa9c9f.

Figure 115: Thrombelastography variables with definitions.

D. Conventional Coagulation Tests (CCT)
Conventional coagulation tests (CCT) obtain values such as prothrombin time (PT),
international normalized ratio (INR), activated partial thromboplastin time (aPTT),
fibrinogen, and platelets (PLTs). Using CCTs in trauma to study the complications and
early indicators of those complications with TXA would be done by comparing the
natural coagulation ability of a patient before being administered TXA to possibly
identify any complication indicators. CCTs are inexpensive and convenient, but they
have a lengthy turnaround time (more than 1 hour). These tests are also primarily useful
to screen for anticoagulants in stable nonbleeding patients and are unable to detect
hyperfibrinolysis which would indicate the need for TXA. However, CCTs use only the
plasma component of blood, whereas TEG uses the whole blood sample. The red blood
cells and platelets within the whole blood sample are important factors in clot formation.

15

Simon, Erica, “The Thromboelastogram (TEG®): A Five-Minute Primer for the Emergency Physician,” December
21, 2016.

Figure 2: Conventional coagulation tests (bottom) versus thrombelastography (top).

2. Methods
The OHSU IRB approved this study to do a retrospective review of outcomes in
trauma patients at risk of exsanguination and hemorrhagic shock from 2017- 2019. By
using prehospital and in-hospital electronic medical records at Oregon Health and
Sciences University (OHSU), patients who received TXA (N=127) for treatment of
trauma-induced hemorrhaging were identified and cross-matched with trauma patients
who had similar ISS scores but did not receive TXA (N=127). Variables such as
demographics, baseline and admission information, TEG results obtained by a
TEG® 5000 Thrombelastograph®, conventional coagulation test results, hospital and
ICU length of stay (LOS), thromboembolic complications, and mortality rates were
collected using in-hospital data and data from the Trauma Quality Improvement
Program (TQIP). SPSS Statistics software was used to analyze the data once it was
gathered and appropriate parametric and non-parametric tests were determined based
on normal distribution.

Patients included in the analysis met the following criteria:
● Age ≥ 15 years of age
● Injury severity score (ISS) ≥ 9
● Admitted to OHSU trauma service
● If receiving TXA, received IV form only

3. Data & Results
A. Demographics
Basic demographics of the patient population included age, sex, race and ethnicity
(Table 1.1). There were no significant differences found between groups. (P <0.05).
The average age of the population was just over 50 years, and sex of the population
was balanced between the groups. While there was no difference in race or ethnicity,
there is an observably larger population of white and non-Hispanic people represented
in the study group. This demographic seems to be closely correlated with Portland,
Oregon’s racial and ethnic demographic based on the recent U.S Census statistics16.
Table 1.1
Age
Sex (% female)

TXA (N= 127)
51.7 ± 20.4
36

No TXA (N=127)
53.4 ± 20.6
28

P-value
0.53
0.18

Ethnicity
Hispanic/Latino
Non-Hispanic/Latino

9
103

3
102

0.10

2

4

4
0

1
2

2
12
101

3
4
98

Race
Asian
Native
Hawaiian/Other
Pacific Islander
American Indian
Black or African
American
Other Race
White

16

0.14

U.S. Census Bureau, Population Estimates Program (PEP), “Oregon Census 2020,” 2020,
https://www.census.gov/quickfacts/OR.

B. Hospital data

Pre-hospital and admission data showed some significant P-values with systolic
blood pressure (SBP), heart rate (HR), and Glasgow Coma Score (GCS) (Table 1.2).
While the data presented are not indicative of hemorrhagic shock, patients who
received TXA have worse vital signs compared to those who did not receive TXA.
Table 1.2
Pre-hospital (EMS) Data
SBP (mean ± SD)
HR (mean ± SD)
GCS (median, IQR)
Admission Data (ED)
SBP (SD deviation)
HR
GCS (median, IQR)

TXA (N= 127)

No TXA (N=127)

P-value

125.75 ± 29.0
93.72 ± 24.7
14 (10, 15)

139.93 ± 28.6
87.03 ± 21.0
14 (11.5, 15)

0.008
0.11
0.45

128.76 ± 37.6
97.1 ± 24.8
14 (4.5, 15)

136.42 ± 24.7
85.5 ± 19.8
15 (13, 15)

0.15
0.003
0.05

C. Injury Data
Groups were cross matched by Injury Severity Score (ISS) and the P-value of 1.0
supports this (Table 1.3). When ISS is calculated, it is done by adding the sum of the
squares of the highest AIS score in the more severely injured regions of the body. When
we look at average AIS scores in each body region between groups, we notice that
there are significantly higher AIS scores in the abdomen, spine, and lower extremity in
the TXA group. While the P-value for penetrating mechanism of injury was not
statistically significant, there were 7% more penetrating injuries in the TXA group than
the non-TXA group. This may be reflected by the more severely injured body regions in
the TXA group. Abdominal and lower extremity injuries are typically indicators of
penetrating injuries as they are areas that become more complicated if a knife or bullet
injures another organ in its path. Though we see this pattern in the AIS scores, ISS may
underestimate the severity of injury, especially if it is penetrating. The New Injury
Severity Score (NISS) has been reported to perform better when predicting survival
because unlike the ISS score which sums the squares of the most severely injured AIS
body regions, the NISS score sums the square of the most severe AIS injuries,
regardless of body region. This means that if someone was stabbed and had
lacerations in multiple organs within one region, the severity of those injuries would be
individually included into the score. We decided to compare the ISS scores with the
NISS scores of the same study population to observe if there was a difference but from
our findings the scores were similar. Since TXA had a higher percent of penetrating
injuries, we expected to see a higher NISS score for this group but there was no

difference found. This may be due to our small sample size and lack of availability for
NISS data since it is relatively new and not as established of a score as ISS.
Table 1.3
AIS

TXA (N= 127)

No TXA (N= 127)

P-value

Head
Face
Neck
Thoracic
Abdomen
Spine
Upper Extremity
Lower Extremity

3 (2, 3.75)
1 (1, 2)
2 (1, 3)
3 (2, 3)
2 (2, 3)
2 (2, 2)
1 (1, 2)
2 (2, 3)

3 (2, 3)
1 (1, 1)
1.5 (1, 3)
2 (2, 3)
2 (1, 3)
2 (2, 2)
1 (1, 2)
2 (1, 2)

0.33
0.56
0.55
0.79
0.04
0.06
0.24
0.00

ISS
MOI, % penetrating

20.39 ± 9.7
9

20.39 ± 9.7
2

1.0
0.1

D. Transport times
Since administration time is vital to the success of TXA effectively working for the
patient, we decided to compare the times between when EMS was notified of the scene
and arrival of the patient to the hospital, then from arrival to admission also taking into
account time spent at the scene and transport time (Table 1.4). There was not enough
complete data in the trauma registry or pre-hospital/EMS data to compare injury time to
TXA administration which is the primary concern as TXA needs to be administered
within 3 hours of the injury to be effective. This may be due to the chaotic scene for
many severely injured patients making documentation difficult. There were no significant
differences in travel times between study groups. All together time from scene to
hospital admission was approximately on average 2 hours. This would leave about an
hour for effective TXA administration which does not leave a lot of time to properly
evaluate and predict a patient’s response to the medication. This finding is concerning
as any predictive measures available would have to be considered after the fact for TXA
administration, but it also supports the need for more frequent TXA use on route in EMS
services so the likelihood of administration within the 3 hours is higher.
Table 1.4
Time EMS notified to Hospital
Admission, minutes
Time of EMS arrival to Hospital
Admission, minutes
Time at Scene, minutes

TXA (N=63)

No TXA (N=68)

P-value

50 (34, 70)

44.5 (36, 58.5)

0.50

38 (26, 50)
15 (9, 22)

36.5 (31, 52.75)
14 (10, 22)

0.41
0.75

Transport time, minutes

19 (15, 30)

23 (17.25, 30)

0.11

E. Clinical outcomes
Basic outcomes of the groups showed no p-values under 0.05 to indicate any
significant differences (Table 1.5). On observation of the statistics we can see that
average hospital length of stay (LOS) was greater in the TXA group than the non-TXA
group with a p-value of 0.09, possibly trending toward significance if the sample
population was larger. The same could probably be said for other values as it was
reported in the CRASH-2 and MATTERS multi-institute clinical trials on TXA that
mortality, and length of stay was significantly less in the TXA group than non-TXA
group. Mortality was 2.7% lower in the TXA group compared to the non-TXA group.
This is not as significant of a difference as we would have predicted to see, but again
this can most likely be accounted for due to the sample size. It should also be noted that
though the hospital LOS for the TXA group was slightly higher, the ICU LOS had a
p-value close to 1.0 when compared to the non-TXA group indicating that there was
little to no difference in ICU LOS, this is similar to the case for ventilator days which was
also near equal between groups.
Table 1.5
Mortality (% died)
Hospital LOS (days)
ICU LOS (days)
Total ventilator (days)

TXA (N=127)
17.3
10 (6, 16.25)
5.7 (2.0, 7.3)
3 (2, 5)

No TXA (N= 127)
20
7 (3, 14)
5.5 (1.0, 8.0)
3 (2, 6)

P-value
0.67
0.09
0.84
0.43

F. Blood products
CRASH-2 and MATTERS clinical trials showed a reduction in blood products
required for patients who received TXA as opposed to those who did not (Table 1.6). In
our study, we did not see any significance between groups and that blood products
required for both groups were fairly equal. While there is a trend in the non-TXA group
having received more units of whole blood, it is not significantly different or clinically
relevant. No significant statement can be made based on our findings on whether TXA
impacted the amount of blood products required.
Table 1.6
Whole blood
Red blood cells
Fresh frozen plasma
Cryoprecipitate
Platelets

TXA (N= 127)

No TXA (N= 127)

P-value

1 (1, 1)

2 (1, 3)

0.09

2.5 (1, 6.25)
4 (2, 6.25)
1.5 (1, 2)
1 (1, 5)

2 (1.5, 5)
3 (2, 4)
1 (1, 1)
2 (1, 2)

0.53
0.65
0.67
0.91

G. Complications
Some studies suggest that TXA could be an independent risk factor for venous
thromboembolisms (VTE), and there needs to be more research done to identify
patients that benefit most from TXA and those who are at risk17. Pulmonary embolisms
(PE) and deep vein thrombosis (DVT) are composites of VTEs. We predicted that out of
any of the complications that could occur with administration of TXA, deep vein
thrombosis (DVT) would be the most likely. While there is a trend toward significance for
DVTs (p=
 0.08), a larger sample size may provide a significant difference (Table 1.7).
There were no significant occurrences of PEs (p=
 0.34) despite that fact that only the
non-TXA group developed PEs. Other complications such as ventilator associated
pneumonia, acute kidney injury, and cardiac arrest were present in both groups but not
significantly different enough to suggest that TXA caused significant harm.
Table 1.7
Deep Vein Thrombosis
Pulmonary Embolism
Ventilator Associated Pneumonia
Acute Kidney Injury
Cardiac Arrest

TXA (%)
31
0
1.7
3.4
6.9

No TXA (%)
31
3.4
6.9
0
6.9

P-value
0.08
0.34
0.56
0.34
0.41

H. Discharge disposition
There were no significant differences in discharge dispositions between groups to
suggest that the TXA group had an increased rate of recovery after trauma (p=
 0.51)
(Table 1.8). Distribution of discharge was fairly equal with most being directly sent
home after treatment. Not all patients had discharge dispositions reported in their
electronic medical record so some values are missing which may affect the trend we
see with our current data.
Table 1.8
Short term general
hospital for
inpatient care
Home w/ health
service
Against medical
advice (AMA)
Home
17

TXA (N= 62)

No TXA (N= 40)

1

3

3

4

1
24

0
17

P-value

0.51

Myers, Sara P and et al., “Tranexamic Acid Administration Is Associated with an Increased Risk of Posttraumatic
Venous Thromboembolism,” The Journal of Trauma and Acute Care Surgery 86, no. 1 (January 2019): 20–27,
https://doi.org/10.1097/TA.0000000000002061.

Skilled nursing
facilities (SNF)
Hospice
Court/Law
enforcement
Inpatient
rehabilitation
Long term care
Psych unit

16
0

7
1

4

0

8
2
3

6
1
1

I. Comparison of thrombelastography (TEG) values
In our analysis of TEG results, there was less available data for the
non-TXA group than the TXA group. This is possibly due to the fact that TXA is
given to patients to assist with hemorrhage control, so patients who received
TXA most likely had more bleeding on admission which would require
coagulation testing. Also, in the TXA group, TEG results were primarily
obtained on admission, prior to administration of TXA, but theoretically a
couple of patients could have received TXA beforehand if their condition
appeared severe enough for immediate administration. Although, this would
only be a handful of patients in the group.
The null hypothesis for our analysis is that there would be no difference
in individual TEG values between groups. The only case where we were able
to reject the null hypothesis was in the case of alpha angle which is a value
used to assess the rate of clot formation. The normal value for alpha angle is
about 53-73 degrees in a healthy person18. Both groups had elevated median
alpha angle values, but the TXA group (73.0°) was lower than the non-TXA
group (76.7°) which could indicate that the rate of clot formation was slower in
the TXA group. In regard to the rest of the TEG values, MA for the TXA group
was 62.1 and 63.0 for the non-TXA group but not significantly different (p=
0.29). Two markers for a hypercoagulation (R < 9, and MA > 64) would be
an indication for risk of thromboembolic complication if TXA were
administered19. Both TXA and non-TXA groups had median R values under 9,
but both median MA values were below the range for hypercoagulation (Table
1.9). This would indicate that there were no predictive markers for either the
TXA or non-TXA group to anticipate VTE complications.
18

Bose, Eliezer MSN, CCRN and Hravnak, Marilyn PhD, ACNP-BC, “Thromboelastography: A Practice Summary for
Nurse Practitioners Treating Hemorrhage,” The Journal for Nurse Practitioners 11, no. 7 (August 2015): 702–9,
https://doi.org/10.1016/j.nurpra.2015.05.006.
19
Spasiano, A. et al., “Early Thromboelastography in Acute Traumatic Coagulopathy: An Observational Study
Focusing on Pre-Hospital Trauma Care.”

While we would have expected a significant difference in LY30
between the groups with the value for TXA being lower, the p-value was only
0.63. Since TXA is an antifibrinolytic medication, the clot lysis at 30 minutes
should have been less. This could be due to the TEG not being sensitive
enough to detect the effects of TXA20.

Table 1.9

TXA (N= 61)

No TXA (N= 28)

P-value

R-time (min)

4.3 (3.5, 5.3)

4.1 (3.3, 5.4)

0.52

K (min)

1.3 (1.1, 1.8)

1.2 (1.1, 1.3)

0.09

Angle (deg)

73.0 (67.6, 76.1)

76.7 (73.1, 77.9)

0.005

MA (mm)

62.1 (56.4, 66.1)

63.0 (57.9, 68.8)

0.29

LY30 (%)

1.1 (0.0, 7.5)

2.0 (0.0, 8.7)

0.63

J. Comparison of Conventional Coagulation Tests (CCT)
Values obtained for conventional coagulation tests were INR, aPPT, and fibrinogen
(Table 2.0). We compared the median and interquartile range for each group and found
a significant difference in fibrinogen level. Normal range for fibrinogen level is 200 to
400 mg/dL21, and both groups were within this range with the TXA group being
significantly less. In healthy people, normal range for INR is 1.1 or below22, both groups
were below this range with no significant differences that would indicate increased risk
for DVTs or PEs. For aPTT the reference range used is 30-40 seconds23. Both groups
were slightly under this range, but neither were significantly different from one another.
APTT is a particularly important value when trying to predict possible complications with
TXA administration because if someone is forming clots too quickly, and they are not
being broken down, then that puts them at risk for DVT.
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The Journal of Trauma and Acute Care Surgery, August 28, 2020, https://doi.org/10.1097/TA.0000000000002932.
21
“Fibrinogen Blood Test,” MedlinePlus, December 3, 202AD,
https://medlineplus.gov/ency/article/003650.htm#:~:text=The%20normal%20range%20is%20200,of%20your%20s
pecific%20test%20results.
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Mayo Clinic Staff, “Prothrombin Time Test,” Mayo Clinic, December 8, 2020,
https://www.mayoclinic.org/tests-procedures/prothrombin-time/about/pac-20384661#:~:text=In%20healthy%20
people%20an%20INR,in%20the%20leg%20or%20lung.
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“Activated Partial Thromboplastin Time,” April 10, 2020,
https://www.labtestsonline.org.au/learning/test-index/aptt#:~:text=The%20aPTT%20test%20measures%20the,XII.

Table 2.0

TXA

No TXA

P-value

INR

1.08 (1.00, 1.23)

1.04 (1.00, 1.20)

0.11

aPPT (sec)

29.00 (25.45, 34.13)
256.5 (190.8, 327.0)

28.00 (25.35, 31.98)

0.25

310.0 (250.0, 382.0)

0.001

Fibrinogen

4. Conclusion
While we would have liked to match our findings to the national trials, there is no
indicator that TXA causes any significant harm to patients who received it. The only
indication of risk that we found was a trend toward significance for DVT occurrences
which may be attributed to OHSUs screening of DVTs as a standard of protocol for
trauma patients. There were no other indications of risk for complications such as
pulmonary embolisms, ventilator associated pneumonia, acute kidney injury, and
cardiac arrest. Unfortunately, unlike the MATTERS trial, we did not find a significant
reduction in blood products used for the TXA group, or a significant difference in
mortality rate. Our lack of significant findings for mortality and blood products may be
attributed to the small sample size and lack of data for some in our study groups.
We suspect that the higher percent of penetrating mechanisms of injury in the TXA
group influenced the longer hospital length of stay for TXA patients as these types of
injuries typically take longer to recover from if internal organs are lacerated. We
matched groups by ISS score to avoid this discrepancy, but this difference in injury
severity was also seen in the significantly higher AIS scores for abdominal and lower
extremity injuries which is where penetrating injuries typically occur. This may be
controlled in future studies by matching groups by using the new injury severity score
(NISS) which has been shown to account for penetrating injury severity more precisely.
One of our goals was to try and correlate any possible complications to
coagulation assays such as TEG and CCT. Since deep vein thrombosis was the only
potential complication we found, we attempted to relate this with the coagulation results.
We did not have test results for every patient in the study which reduced our sample
even more, but there were some significant findings obtained. A factor that we initially
did not account for prior to data collection for the TXA group was whether the time of
when the sample for the coagulation tests was drawn before or after TXA
administration. Since most samples are drawn on admission, we made the assumption
that this was done before TXA was administered, but this should be controlled in future
research for accuracy of findings. While both groups had elevated alpha angles from the
normal value, this may be due to any traumatic hemorrhaging, but no studies have been
done to confirm this. A lower alpha angle on admission in the TXA group would indicate

that the rate at which thrombin is released to convert fibrinogen to fibrin in the clotting
cascade is slower for the TXA group. Based on this, TXA would act to preserve any
clots formed and therefore help with recovery rather than sabotage it. Therefore, we
cannot conclude that lower alpha angle would be an indicator for risk with TXA
administration. One of the risk factors for administration of TXA would be
hypercoagulation, which is best indicated by MA and R TEG values. There was no
significant indication that the TXA group was at risk based off of these values. A reason
for lack of findings with TEG results may be due to the machine not being sensitive
enough to indicate changes in fibrinolysis.
When we compared CCT values, we observed INR, aPPT, and fibrinogen values.
While all groups had values within normal range, fibrinogen was the only value that had
a significant difference between groups with the TXA group having lower levels. Again,
we make the assumption that samples were drawn prior to any administration of TXA.
For patients arriving with lower fibrinogen levels, clots typically have difficulty forming.
While the TXA group had lower fibrinogen, it was not out of the normal range so we
cannot associate any risk or benefit caused by TXA.
The basis of this study was to better understand TXAs use in treatment of
hemorrhaging secondary to traumatic injury. We went into it with a similar hypothesis to
national studies such as the CRASH-2 and 3, and MATTERS trials that TXA will
significantly reduce the rate of mortality, and blood products required with no
attributable risk to patients. Ultimately our goal is to get TXA into EMS services so that it
can be administered sooner and improve outcomes and recovery. Our hypothesis was
partially correct as we found no indication that TXA causes any significant harm to
patients, and that it did reduce mortality rate. This study serves as a start point for
further research into potential complications of TXA and ways to predict and prevent
these complications through coagulation assays. We intend to add onto this study with
another retrospective analysis as more data becomes available for 2020.

